Arno Therapeutics, Inc. HomeAbout UsPipelineInvestor RelationsContact Us
Arno Therapeutics is a biopharmaceutical company focused on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs
Arno Theraoeutics, Inc.
Recent Press Releases In the news Contact

December 10, 2014
Arno Therapeutics Doses First Patient in Expansion Stage of Modified Phase I/II Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors more »

December 9, 2014
Arno Therapeutics to Present Data Further Validating Diagnostic Development of CDx for Onapristone at San Antonio Breast Cancer Symposium 2014 more »

December 4, 2014
Arno Therapeutics Appoints Alexander Zukiwski, M.D. to Board of Directors more »

November 24, 2014
Arno Therapeutics to Present at LD Micro Conference 2014 more »

November 14, 2014
Arno Therapeutics Reports Third Quarter 2014 Financial and Business Update more »

Oct. 29, 2014
Arno Therapeutics' Executive Selected to Present at 5th Annual Clinical Affairs and Regulatory Approvals for Diagnostics Conference more »

View all Press Releases


May 23, 2014
Express Yourself: Arno, University of Minnesota pursue gene expression in hopes of developing a companion diagnostic more »

May 19, 2014
Do the Math: Ram Selvaraju on the Appeal of Biotechs in Orphan Diseases more »

May 9, 2014
Maxim: ARNI - Clinical progress on track; Onapristone in two dose escalation trials; Reiterating Buy and $6 price target more »

January 22, 2014
Maxim: ARNI - Onapristone now in clinical development; Revising estimates; Reiterating Buy and $6 price target more »

July 15, 2013
Orphan-Drug Marketing - Medical Marketing & Media (MM&M) eBook more »

July 8, 2013
APRs in CTCs - Drug Discovery News more »

June 13, 2013
Arno Therapeutics’ strategy is to develop onapristone companion diagnostics for each indication - Biopharm Insight more »

View All News


Arno Therapeutics, Inc.
200 Route 31 North
Suite 104
Flemington, NJ 08822

(862) 703-7170 Main
(908) 237-0071 Fax
info@arnothera.com